Objective： To study the clinical efficacy of electroacupuncture （EA） on treating knee osteoarthritis （KOA） of Shen （肾）-Sui （（肾） insufficiency （SSI） syndrome type. Methods： A total of 245 patients （279 ...Objective： To study the clinical efficacy of electroacupuncture （EA） on treating knee osteoarthritis （KOA） of Shen （肾）-Sui （（肾） insufficiency （SSI） syndrome type. Methods： A total of 245 patients （279 knees） of KOA-SSI were randomly assigned to two groups by lottery： 141 knees in the treatment group and 138 knees in the control group. The treatment group was managed with EA at the dominant points of Neixiyan （Ex-LE4） and Waixiyan （Ex-LE5） as well as the conjugate points of Xuanzhong （GB39） and Taixi （KI3） for 30 min, once a day, with 15 days as one course; 2 courses were applied with a 5-day interval in between. The control group was treated with intra-articular injection of 2 mL hyaluronic acid into the affected joint every 7 days for 5 times in total. The clinical effects on the patients in different stages were observed, and their symptom scores of knee and contents of cytokines, including interleukin-1 （IL-1）, interleukin-6 （IL-6）, tumor necrosis factor- α （TNF- α）, prostaglandin E2, （PGE2α） and matrix metalloproteinases-3 （MMP-3）, in the knee joint fluid were measured before and after treatment. Results： The study was completed in 235 patients （263 knees）; four patients （7 knees） in the treatment group and six patients （9 knees） in the control group dropped out. Comparison of therapeutic effects （excellent and effective rates） between the two groups showed insignificant differences （P〉0.05）. Symptom scores of knee and contents of cytokines in the knee fluid after treatment were lowered significantly in the patients of stage Ⅰ -Ⅲ in both groups （P〈0.05 or P〈0.01）. However, the lowering of the total symptom score of knee in the patients of stage Ⅲ in the treatment group was more significant （P〈0.05）. Conclusions： EA could effectively alleviate the clinical symptoms in KOA patients of stage m, showing an effect superior to that of hyaluronic acid. EA also shows action in suppressing the secretion of IL-1, IL-6, TNF-α, PGE2α and MMP-3 in the knee fluid.展开更多
目的:探讨硫酸氨基葡萄糖联合参麦注射液治疗膝骨性关节炎的疗效。方法:取膝骨性关节炎患者120例作为研究对象,随机分为联合组和对照组,每组各60例。对照组单纯给予硫酸氨基葡萄糖治疗,联合组给予硫酸氨基葡萄糖(0.5g/次,3次/天)联合参...目的:探讨硫酸氨基葡萄糖联合参麦注射液治疗膝骨性关节炎的疗效。方法:取膝骨性关节炎患者120例作为研究对象,随机分为联合组和对照组,每组各60例。对照组单纯给予硫酸氨基葡萄糖治疗,联合组给予硫酸氨基葡萄糖(0.5g/次,3次/天)联合参麦注射液(每次每膝5 m L,每周注射1次)治疗,连续治疗6周,观察两组患者临床疗效。结果:联合组临床治疗总有效率为91.67%,对照组为78.33%,两组差异有统计学意义(P<0.05);治疗后,联合组患者膝关节骨性关节炎自评量表(WOMAC)改善较对照组明显,差异有统计学意义(P<0.05);联合组和对照患者治疗不良反应发生率无显著差异;治疗后,两组患者血清IL-17、IL-18浓度水平明显下降,转化生长因子β(TGF-β)、胰岛素样生长因子1(IGF-1)、成纤维细胞生长因子2(FGF-2)浓度水平明显上升;联合组患者血清IL-17、IL-18浓度水平下降明显优于对照组,TGF-β、IGF-1、FGF-2浓度水平上升明显优于对照组,差异均有统计学意义(P<0.05)。结论:联合组治疗膝骨性关节炎的疗效显著增加,不良反应发生率较低,其作用机制可能与降低血清IL-17、IL-18浓度水平和提高TGF-β、IGF-1、FGF-2浓度水平有关。展开更多
基金Supported by the National Natural Science Foundation of China (No.30873277)the CHEN Ke-ji Development Fund of Integrative Medicine(No.CKJ2008003)
文摘Objective： To study the clinical efficacy of electroacupuncture （EA） on treating knee osteoarthritis （KOA） of Shen （肾）-Sui （（肾） insufficiency （SSI） syndrome type. Methods： A total of 245 patients （279 knees） of KOA-SSI were randomly assigned to two groups by lottery： 141 knees in the treatment group and 138 knees in the control group. The treatment group was managed with EA at the dominant points of Neixiyan （Ex-LE4） and Waixiyan （Ex-LE5） as well as the conjugate points of Xuanzhong （GB39） and Taixi （KI3） for 30 min, once a day, with 15 days as one course; 2 courses were applied with a 5-day interval in between. The control group was treated with intra-articular injection of 2 mL hyaluronic acid into the affected joint every 7 days for 5 times in total. The clinical effects on the patients in different stages were observed, and their symptom scores of knee and contents of cytokines, including interleukin-1 （IL-1）, interleukin-6 （IL-6）, tumor necrosis factor- α （TNF- α）, prostaglandin E2, （PGE2α） and matrix metalloproteinases-3 （MMP-3）, in the knee joint fluid were measured before and after treatment. Results： The study was completed in 235 patients （263 knees）; four patients （7 knees） in the treatment group and six patients （9 knees） in the control group dropped out. Comparison of therapeutic effects （excellent and effective rates） between the two groups showed insignificant differences （P〉0.05）. Symptom scores of knee and contents of cytokines in the knee fluid after treatment were lowered significantly in the patients of stage Ⅰ -Ⅲ in both groups （P〈0.05 or P〈0.01）. However, the lowering of the total symptom score of knee in the patients of stage Ⅲ in the treatment group was more significant （P〈0.05）. Conclusions： EA could effectively alleviate the clinical symptoms in KOA patients of stage m, showing an effect superior to that of hyaluronic acid. EA also shows action in suppressing the secretion of IL-1, IL-6, TNF-α, PGE2α and MMP-3 in the knee fluid.
文摘目的:探讨硫酸氨基葡萄糖联合参麦注射液治疗膝骨性关节炎的疗效。方法:取膝骨性关节炎患者120例作为研究对象,随机分为联合组和对照组,每组各60例。对照组单纯给予硫酸氨基葡萄糖治疗,联合组给予硫酸氨基葡萄糖(0.5g/次,3次/天)联合参麦注射液(每次每膝5 m L,每周注射1次)治疗,连续治疗6周,观察两组患者临床疗效。结果:联合组临床治疗总有效率为91.67%,对照组为78.33%,两组差异有统计学意义(P<0.05);治疗后,联合组患者膝关节骨性关节炎自评量表(WOMAC)改善较对照组明显,差异有统计学意义(P<0.05);联合组和对照患者治疗不良反应发生率无显著差异;治疗后,两组患者血清IL-17、IL-18浓度水平明显下降,转化生长因子β(TGF-β)、胰岛素样生长因子1(IGF-1)、成纤维细胞生长因子2(FGF-2)浓度水平明显上升;联合组患者血清IL-17、IL-18浓度水平下降明显优于对照组,TGF-β、IGF-1、FGF-2浓度水平上升明显优于对照组,差异均有统计学意义(P<0.05)。结论:联合组治疗膝骨性关节炎的疗效显著增加,不良反应发生率较低,其作用机制可能与降低血清IL-17、IL-18浓度水平和提高TGF-β、IGF-1、FGF-2浓度水平有关。
